307 related articles for article (PubMed ID: 37272701)
1. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract][Full Text] [Related]
2. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
3. The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.
Baumli S; Hole AJ; Wang LZ; Noble ME; Endicott JA
Structure; 2012 Oct; 20(10):1788-95. PubMed ID: 22959624
[TBL] [Abstract][Full Text] [Related]
4. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
Karati D; Mahadik KSR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
[TBL] [Abstract][Full Text] [Related]
5. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S; Whipp E; Walker J; Zhang P; Beaver L; Williams K; Orwick S; Ravikrishnan J; Walker B; Perry E; Gregory C; Purcell M; Pan A; Yan P; Alinari L; Johnson AJ; Frigault MM; Greer JM; Hamdy A; Izumi R; Mo X; Sampath D; Woyach J; Blachly J; Byrd JC; Lapalombella R
Leukemia; 2023 Feb; 37(2):326-338. PubMed ID: 36376377
[TBL] [Abstract][Full Text] [Related]
6. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.
Mbonye U; Wang B; Gokulrangan G; Shi W; Yang S; Karn J
J Biol Chem; 2018 Jun; 293(26):10009-10025. PubMed ID: 29743242
[TBL] [Abstract][Full Text] [Related]
8. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
10. P-TEFb Kinase Activity Is Essential for Global Transcription, Resumption of Meiosis and Embryonic Genome Activation in Pig.
Oqani RK; Lin T; Lee JE; Choi KM; Shin HY; Jin DI
PLoS One; 2016; 11(3):e0152254. PubMed ID: 27011207
[TBL] [Abstract][Full Text] [Related]
11. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
12. The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.
Oqani RK; Kim HR; Diao YF; Park CS; Jin DI
BMC Dev Biol; 2011 Jun; 11():33. PubMed ID: 21639898
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract][Full Text] [Related]
14. Regulation of P-TEFb elongation complex activity by CDK9 acetylation.
Fu J; Yoon HG; Qin J; Wong J
Mol Cell Biol; 2007 Jul; 27(13):4641-51. PubMed ID: 17452463
[TBL] [Abstract][Full Text] [Related]
15. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Olson CM; Jiang B; Erb MA; Liang Y; Doctor ZM; Zhang Z; Zhang T; Kwiatkowski N; Boukhali M; Green JL; Haas W; Nomanbhoy T; Fischer ES; Young RA; Bradner JE; Winter GE; Gray NS
Nat Chem Biol; 2018 Feb; 14(2):163-170. PubMed ID: 29251720
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes.
Mbonye UR; Gokulrangan G; Datt M; Dobrowolski C; Cooper M; Chance MR; Karn J
PLoS Pathog; 2013; 9(5):e1003338. PubMed ID: 23658523
[TBL] [Abstract][Full Text] [Related]
19. G-actin participates in RNA polymerase II-dependent transcription elongation by recruiting positive transcription elongation factor b (P-TEFb).
Qi T; Tang W; Wang L; Zhai L; Guo L; Zeng X
J Biol Chem; 2011 Apr; 286(17):15171-81. PubMed ID: 21378166
[TBL] [Abstract][Full Text] [Related]
20. Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-loop.
Wang Y; Dow EC; Liang YY; Ramakrishnan R; Liu H; Sung TL; Lin X; Rice AP
J Biol Chem; 2008 Nov; 283(48):33578-84. PubMed ID: 18829461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
